Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 166 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine, NPH human insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Greenbrae, California • Mission Hills, California • San Diego, California + 22 more
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Inhaled Insulin (Exubera)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 63 more
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
diabetes self-management education
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
35 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Austin, Texas
Conditions
Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
pump, insulin aspart
Device · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Witchita, Kansas + 3 more
Conditions
Diabetes Mellitus
Interventions
Alogliptin and insulin, Insulin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 42 more
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, LY2189265, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Concord, California • La Mesa, California • Lancaster, California + 33 more
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
118
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS), Continuous Glucose Monitor (CGM) + Usual Care
Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Diabetes Mellitus
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
88
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more